Epigenetic therapy for solid tumors: Highlighting the impact of tumor hypoxia

Genes

Volumn 6, Issue 4, 2015, Pages 935-956

  Ramachandran, Shaliny ^a   Ient, Jonathan ^a   Göttgen, Eva Leonne ^a   Krieg, Adam J ^b   Hammond, Ester M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

DNA methylation; Epigenetic drugs; Gene repression; Histone deacetylation; Histone methylation; Tumor hypoxia

Indexed keywords

AZACITIDINE; BELINOSTAT; BORTEZOMIB; BRCA1 PROTEIN; CASPASE; CISPLATIN; DECITABINE; DNA; DNA METHYLTRANSFERASE; ENTINOSTAT; ERLOTINIB; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; PANOBINOSTAT; ROMIDEPSIN; SUPPRESSOR OF CYTOKINE SIGNALING; TOPOTECAN; VALPROIC ACID; VORINOSTAT;

ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CHEMICAL MODIFICATION; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DNA MODIFICATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE REPRESSION; HEMATOLOGIC MALIGNANCY; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HYPOXIA; KIDNEY CANCER; LUNG CANCER; MELANOMA; MONOTHERAPY; NON SMALL CELL LUNG CANCER; ONCOGENE; OVARY TUMOR; PANCREAS CANCER; PROMOTER REGION; REVIEW; SMALL CELL LUNG CANCER; SOLID TUMOR; THERAPY RESISTANCE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

EID: 84942778310     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes6040935     Document Type: Review

References (118)

1. Venkatesh, S.; Workman, J.L. Histone exchange, chromatin structure and the regulation of transcription. Nat. Rev. Mol. Cell Biol. 2015, 16, 178–189
2. Melvin, A.; Rocha, S. Chromatin as an oxygen sensor and active player in the hypoxia response. Cell. Signal. 2012, 24, 35–43
3. Kanwal, R.; Gupta, S. Epigenetic modifications in cancer. Clin. Genet. 2012, 81, 303–311
4. Tian, X.; Zhang, S.; Liu, H.M.; Zhang, Y.B.; Blair, C.A.; Mercola, D.; Sassone-Corsi, P.; Zi, X. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: New targets for cancer therapy and prevention. Curr. Cancer Drug Targets 2013, 13, 558–579
5. Cao, R.; Wang, L.; Wang, H.; Xia, L.; Erdjument-Bromage, H.; Tempst, P.; Jones, R.S.; Zhang, Y. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 2002, 298, 1039–1043
6. Ning, X.; Shi, Z.; Liu, X.; Zhang, A.; Han, L.; Jiang, K.; Kang, C.; Zhang, Q. DNMT1 and EZH2 mediated methylation silences the microRNA-200B/A/429 gene and promotes tumor progression. Cancer Lett. 2015, 359, 198–205
7. Graham, J.S.; Kaye, S.B.; Brown, R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur. J. Cancer 2009, 45, 1129–1136
8. Blackledge, N.P.; Zhou, J.C.; Tolstorukov, M.Y.; Farcas, A.M.; Park, P.J.; Klose, R.J. CpG islands recruit a histone H3 lysine 36 demethylase. Mol. Cell 2010, 38, 179–190
9. Sarkar, S.; Goldgar, S.; Byler, S.; Rosenthal, S.; Heerboth, S. Demethylation and re-expression of epigenetically silenced tumor suppressor genes: Sensitization of cancer cells by combination therapy. Epigenomics 2013, 5, 87–94
10. Sarkar, S.; Horn, G.; Moulton, K.; Oza, A.; Byler, S.; Kokolus, S.; Longacre, M. Cancer development, progression, and therapy: An epigenetic overview. Int. J. Mol. Sci. 2013, 14, 21087–21113
11. Glasspool, R.M.; Teodoridis, J.M.; Brown, R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer 2006, 94, 1087–1092
12. Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S. Drug resistance in cancer: An overview. Cancers 2014, 6, 1769–1792
13. Jin, W.; Chen, L.; Chen, Y.; Xu, S.G.; Di, G.H.; Yin, W.J.; Wu, J.; Shao, Z.M. UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer. Breast Cancer Res. Treat. 2010, 123, 359–373
14. Zhang, C.; Li, H.; Zhou, G.; Zhang, Q.; Zhang, T.; Li, J.; Zhang, J.; Hou, J.; Liew, C.T.; Yin, D. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells. J. Pathol. 2007, 212, 134–142
15. Kim, M.H.; Kim, M.S.; Kim, W.; Kang, M.A.; Cacalano, N.A.; Kang, S.B.; Shin, Y.J.; Jeong, J.H. Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells. PLoS ONE 2015, 10, e0123133
16. Kwong, J.; Lo, K.W.; Chow, L.S.; Chan, F.L.; To, K.F.; Huang, D.P. Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. Int. J. Cancer 2005, 113, 386–392
17. Wang, T.; Liu, H.; Chen, Y.; Liu, W.; Yu, J.; Wu, G. Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. J. Exp. Clin. Cancer Res. 2009, doi:10.1186/1756-9966-28-160
18. Tong, J.H.; Ng, D.C.; Chau, S.L.; So, K.K.; Leung, P.P.; Lee, T.L.; Lung, R.W.; Chan, M.W.; Chan, A.W.; Lo, K.W., et al. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010, doi:10.1186/1471-2407-10-253
19. Shu, X.S.; Li, L.; Ji, M.; Cheng, Y.; Ying, J.; Fan, Y.; Zhong, L.; Liu, X.; Tsao, S.W.; Chan, A.T., et al. FEZF2, a novel 3P14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. Carcinogenesis 2013, 34, 1984–1993
20. Olcina, M.M.; O’Dell, S.; Hammond, E.M. Targeting chromatin to improve radiation response. Br. J. Radiol. 2015, doi:10.1259/bjr.20140649
21. Song, S.H.; Han, S.W.; Bang, Y.J. Epigenetic-based therapies in cancer: Progress to date. Drugs 2011, 71, 2391–2403
22. Nebbioso, A.; Carafa, V.; Benedetti, R.; Altucci, L. Trials with “epigenetic” drugs: An update. Mol. Oncol. 2012, 6, 657–682
23. Wongtrakoongate, P. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries. World J. Stem Cells 2015, 7, 137–148
24. Nguyen, C.T.; Weisenberger, D.J.; Velicescu, M.; Gonzales, F.A.; Lin, J.C.; Liang, G.; Jones, P.A. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res. 2002, 62, 6456–6461
25. Momparler, R.L.; Momparler, L.F.; Samson, J. Comparison of the antileukemic activity of 5-Aza-2'-deoxycytidine, 1-α-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk. Res. 1984, 8, 1043–1049
26. Fuks, F.; Burgers, W.A.; Brehm, A.; Hughes-Davies, L.; Kouzarides, T. DNA methyltransferase dnmt1 associates with histone deacetylase activity. Nat. Genet. 2000, 24, 88–91
27. Robertson, K.D.; Ait-Si-Ali, S.; Yokochi, T.; Wade, P.A.; Jones, P.L.; Wolffe, A.P. DNMT1 forms a complex with RB, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 2000, 25, 338–342
28. Mottamal, M.; Zheng, S.; Huang, T.L.; Wang, G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015, 20, 3898–3941
29. Mund, C.; Lyko, F. Epigenetic cancer therapy: Proof of concept and remaining challenges. BioEssays News Rev. Mol. Cell. Dev. Biol. 2010, 32, 949–957
30. Azad, N.; Zahnow, C.A.; Rudin, C.M.; Baylin, S.B. The future of epigenetic therapy in solid tumours—Lessons from the past. Nat. Rev. Clin. Oncol. 2013, 10, 256–266
31. Hutt, D.M.; Roth, D.M.; Vignaud, H.; Cullin, C.; Bouchecareilh, M. The histone deacetylase inhibitor, vorinostat, represses hypoxia inducible factor 1α expression through translational inhibition. PLoS ONE 2014, 9, e106224
32. Lee, H.Z.; Kwitkowski, V.E.; del Valle, P.L.; Ricci, M.S.; Saber, H.; Habtemariam, B.A.; Bullock, J.; Bloomquist, E.; Li Shen, Y.; Chen, X.H.;. Fda approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin. Cancer Res. 2015, doi:10.1158/1078-0432.CCR-14-3119
33. Slingerland, M.; Guchelaar, H.J.; Gelderblom, H. Histone deacetylase inhibitors: An overview of the clinical studies in solid tumors. AntiCancer Drugs 2014, 25, 140–149
34. Molife, L.R.; de Bono, J.S. Belinostat: Clinical applications in solid tumors and lymphoma. Expert Opin. Investig. Drugs 2011, 20, 1723–1732
35. Brown, J.M.; Giaccia, A.J. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58, 1408–1416
36. Vansteenkiste, J.; van Cutsem, E.; Dumez, H.; Chen, C.; Ricker, J.L.; Randolph, S.S.; Schoffski, P. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Investig. New Drugs 2008, 26, 483–488
37. Luu, T.H.; Morgan, R.J.; Leong, L.; Lim, D.; McNamara, M.; Portnow, J.; Frankel, P.; Smith, D.D.; Doroshow, J.H.; Wong, C., et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California cancer consortium study. Clin. Cancer Res. 2008, 14, 7138–7142
38. Modesitt, S.C.; Sill, M.; Hoffman, J.S.; Bender, D.P. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study. Gynecol. Oncol. 2008, 109, 182–186
39. Blumenschein, G.R., Jr.; Kies, M.S.; Papadimitrakopoulou, V.A.; Lu, C.; Kumar, A.J.; Ricker, J.L.; Chiao, J.H.; Chen, C.; Frankel, S.R. Phase II trial of the histone deacetylase inhibitor vorinostat (zolinza, suberoylanilide hydroxamic acid, saha) in patients with recurrent and/or metastatic head and neck cancer. Investig. New Drugs 2008, 26, 81–87
40. Ramalingam, S.S.; Maitland, M.L.; Frankel, P.; Argiris, A.E.; Koczywas, M.; Gitlitz, B.; Thomas, S.; Espinoza-Delgado, I.; Vokes, E.E.; Gandara, D.R., et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 56–62
41. Stadler, W.M.; Margolin, K.; Ferber, S.; McCulloch, W.; Thompson, J.A. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 2006, 5, 57–60
42. Schrump, D.S.; Fischette, M.R.; Nguyen, D.M.; Zhao, M.; Li, X.; Kunst, T.F.; Hancox, A.; Hong, J.A.; Chen, G.A.; Kruchin, E., et al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clin. Cancer Res. 2008, 14, 188–198
43. Whitehead, R.P.; Rankin, C.; Hoff, P.M.; Gold, P.J.; Billingsley, K.G.; Chapman, R.A.; Wong, L.; Ward, J.H.; Abbruzzese, J.L.; Blanke, C.D. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A southwest oncology group study (S0336). Investig. New Drugs 2009, 27, 469–475
44. Molife, L.R.; Attard, G.; Fong, P.C.; Karavasilis, V.; Reid, A.H.; Patterson, S.; Riggs, C.E., Jr.; Higano, C.; Stadler, W.M.; McCulloch, W., et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACI) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 2010, 21, 109–113
45. Otterson, G.A.; Hodgson, L.; Pang, H.; Vokes, E.E. Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (cancer and leukemia group B 30304). J. Thoracic Oncol. 2010, 5, 1644–1648
46. Giaccone, G.; Rajan, A.; Berman, A.; Kelly, R.J.; Szabo, E.; Lopez-Chavez, A.; Trepel, J.; Lee, M.J.; Cao, L.; Espinoza-Delgado, I., et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J. Clin. Oncol. 2011, 29, 2052–2059
47. Hainsworth, J.D.; Infante, J.R.; Spigel, D.R.; Arrowsmith, E.R.; Boccia, R.V.; Burris, H.A. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Investig. 2011, 29, 451–455
48. Wang, H.; Cao, Q.; Dudek, A.Z. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 2012, 32, 1027–1031
49. Hauschild, A.; Trefzer, U.; Garbe, C.; Kaehler, K.C.; Ugurel, S.; Kiecker, F.; Eigentler, T.; Krissel, H.; Schott, A.; Schadendorf, D. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res. 2008, 18, 274–278
50. Witta, S.E.; Jotte, R.M.; Konduri, K.; Neubauer, M.A.; Spira, A.I.; Ruxer, R.L.; Varella-Garcia, M.; Bunn, P.A., Jr.; Hirsch, F.R. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J. Clin. Oncol. 2012, 30, 2248–2255
51. Juergens, R.A.; Wrangle, J.; Vendetti, F.P.; Murphy, S.C.; Zhao, M.; Coleman, B.; Sebree, R.; Rodgers, K.; Hooker, C.M.; Franco, N., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011, 1, 598–607
52. Candelaria, M.; Gallardo-Rincon, D.; Arce, C.; Cetina, L.; Aguilar-Ponce, J.L.; Arrieta, O.; Gonzalez-Fierro, A.; Chavez-Blanco, A.; de la Cruz-Hernandez, E.; Camargo, M.F., et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann. Oncol. 2007, 18, 1529–1538
53. Coronel, J.; Cetina, L.; Pacheco, I.; Trejo-Becerril, C.; Gonzalez-Fierro, A.; de la Cruz-Hernandez, E.; Perez-CARDenas, E.; Taja-Chayeb, L.; Arias-Bofill, D.; Candelaria, M., et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med. Oncol. 2011, 28, S540–S546
54. Bauman, J.; Verschraegen, C.; Belinsky, S.; Muller, C.; Rutledge, T.; Fekrazad, M.; Ravindranathan, M.; Lee, S.J.; Jones, D. A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. Cancer Chemother. Pharmacol. 2012, 69, 547–554
55. Fu, S.; Hu, W.; Iyer, R.; Kavanagh, J.J.; Coleman, R.L.; Levenback, C.F.; Sood, A.K.; Wolf, J.K.; Gershenson, D.M.; Markman, M., et al. Phase 1B-2A study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011, 117, 1661–1669
56. Appleton, K.; Mackay, H.J.; Judson, I.; Plumb, J.A.; McCormick, C.; Strathdee, G.; Lee, C.; Barrett, S.; Reade, S.; Jadayel, D., et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 2007, 25, 4603–4609
57. Pohlmann, P.; DiLeone, L.P.; Cancella, A.I.; Caldas, A.P.; Dal Lago, L.; Campos, O., Jr.; Monego, E.; Rivoire, W.; Schwartsmann, G. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am. J. Clin. Oncol. 2002, 25, 496–501
58. Hammond, E.M.; Asselin, M.C.; Forster, D.; O’Connor, J.P.; Senra, J.M.; Williams, K.J. The meaning, measurement and modification of hypoxia in the laboratory and the clinic. Clin. Oncol. 2014, 26, 277–288
59. Cosse, J.P.; Michiels, C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anti-Cancer Agents Med. Chem. 2008, 8, 790–797
60. Nordsmark, M.; Bentzen, S.M.; Rudat, V.; Brizel, D.; Lartigau, E.; Stadler, P.; Becker, A.; Adam, M.; Molls, M.; Dunst, J., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 2005, 77, 18–24
61. Semenza, G.L. Hypoxia-inducible factor 1: Master regulator of O2 homeostasis. Curr. Opin. Genet. Dev. 1998, 8, 588–594
62. Nguyen, M.P.; Lee, S.; Lee, Y.M. Epigenetic regulation of hypoxia inducible factor in diseases and therapeutics. Arch. Pharm. Res. 2013, 36, 252–263
63. Ellis, L.; Hammers, H.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009, 280, 145–153
64. Liang, D.; Kong, X.; Sang, N. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle 2006, 5, 2430–2435
65. Rankin, E.B.; Giaccia, A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008, 15, 678–685
66. Luo, D.; Wang, Z.; Wu, J.; Jiang, C.; Wu, J. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. BioMed Res. Int. 2014, doi:10.1155/2014/409272
67. Liao, D.; Johnson, R.S. Hypoxia: A key regulator of angiogenesis in cancer. Cancer Metast. Rev. 2007, 26, 281–290
68. Albinger-Hegyi, A.; Stoeckli, S.J.; Schmid, S.; Storz, M.; Iotzova, G.; Probst-Hensch, N.M.; Rehrauer, H.; Tinguely, M.; Moch, H.; Hegyi, I. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int. J. Cancer 2010, 126, 2653–2662
69. Le, Q.T.; Harris, J.; Magliocco, A.M.; Kong, C.S.; Diaz, R.; Shin, B.; Cao, H.; Trotti, A.; Erler, J.T.; Chung, C.H., et al. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation therapy oncology group trial 90-03. J. Clin. Oncol. 2009, 27, 4281–4286
70. Sakai, M.; Kato, H.; Sano, A.; Tanaka, N.; Inose, T.; Kimura, H.; Sohda, M.; Nakajima, M.; Kuwano, H. Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2009, 16, 2494–2501
71. Erler, J.T.; Bennewith, K.L.; Nicolau, M.; Dornhofer, N.; Kong, C.; Le, Q.T.; Chi, J.T.; Jeffrey, S.S.; Giaccia, A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440, 1222–1226
72. Johnson, A.B.; Denko, N.; Barton, M.C. Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. Mutat. Res. 2008, 640, 174–179
73. Kim, M.S.; Kwon, H.J.; Lee, Y.M.; Baek, J.H.; Jang, J.E.; Lee, S.W.; Moon, E.J.; Kim, H.S.; Lee, S.K.; Chung, H.Y., et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Med. 2001, 7, 437–443
74. Lee, S.H.; Kim, J.; Kim, W.H.; Lee, Y.M. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene 2009, 28, 184–194
75. Lu, Y.; Chu, A.; Turker, M.S.; Glazer, P.M. Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol. Cell. Biol. 2011, 31, 3339–3350
76. Lu, Y.; Wajapeyee, N.; Turker, M.S.; Glazer, P.M. Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1. Cell Rep. 2014, 8, 501–513
77. Okami, J.; Simeone, D.M.; Logsdon, C.D. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res. 2004, 64, 5338–5346
78. Murai, M.; Toyota, M.; Suzuki, H.; Satoh, A.; Sasaki, Y.; Akino, K.; Ueno, M.; Takahashi, F.; Kusano, M.; Mita, H., et al. Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin. Cancer Res. 2005, 11, 1021–1027
79. Olcina, M.M.; Leszczynska, K.B.; Senra, J.M.; Isa, N.F.; Harada, H.; Hammond, E.M. H3K9me3 facilitates hypoxia-induced p53-dependent apoptosis through repression of APAK. Oncogene 2015, doi:10.1038/onc.2015.134
80. Olcina, M.M.; Foskolou, I.P.; Anbalagan, S.; Senra, J.M.; Pires, I.M.; Jiang, Y.; Ryan, A.J.; Hammond, E.M. Replication stress and chromatin context link ATM activation to a role in DNA replication. Mol. Cell 2013, 52, 758–766
81. Scanlon, S.E.; Glazer, P.M. Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins. Mol. Cancer Res. 2014, 12, 1016–1028
82. Nakamura, J.; Kitajima, Y.; Kai, K.; Hashiguchi, K.; Hiraki, M.; Noshiro, H.; Miyazaki, K. Expression of hypoxic marker ca ix is regulated by site-specific DNA methylation and is associated with the histology of gastric cancer. Am. J. Pathol. 2011, 178, 515–524
83. Huang, K.T.; Mikeska, T.; Dobrovic, A.; Fox, S.B. DNA methylation analysis of the HIF-1[1] Prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas. Histopathology 2010, 57, 451–460
84. Rawluszko, A.A.; Bujnicka, K.E.; Horbacka, K.; Krokowicz, P.; Jagodzinski, P.P. Expression and DNA methylation levels of Prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer. BMC Cancer 2013, doi:10.1186/1471-2407-13-526
85. Liu, Q.; Liu, L.; Zhao, Y.; Zhang, J.; Wang, D.; Chen, J.; He, Y.; Wu, J.; Zhang, Z.; Liu, Z. Hypoxia induces genomic DNA demethylation through the activation of HIF-1[1] and transcriptional upregulation of MAT2A in hepatoma cells. Mol. Cancer Ther. 2011, 10, 1113–1123
86. Skowronski, K.; Dubey, S.; Rodenhiser, D.; Coomber, B. Ischemia dysregulates DNA methyltransferases and p16INK4a methylation in human colorectal cancer cells. Epigenetics 2010, 5, 547–556
87. Shahrzad, S.; Bertrand, K.; Minhas, K.; Coomber, B.L. Induction of DNA hypomethylation by tumor hypoxia. Epigenetics 2007, 2, 119–125
88. Mariani, C.J.; Vasanthakumar, A.; Madzo, J.; Yesilkanal, A.; Bhagat, T.; Yu, Y.; Bhattacharyya, S.; Wenger, R.H.; Cohn, S.L.; Nanduri, J., et al. Tet1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Rep. 2014, 7, 1343–1352
89. Hattori, M.; Yokoyama, Y.; Hattori, T.; Motegi, S.I.; Amano, H.; Hatada, I.; Ishikawa, O. Global DNA hypomethylation and hypoxia-induced expression of the ten eleven translocation (TET) family, TET1, in scleroderma fibroblasts. Exp. Dermatol. 2015, doi:10.1111/exd.12767
90. Chen, H.; Yan, Y.; Davidson, T.L.; Shinkai, Y.; Costa, M. Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells. Cancer Res. 2006, 66, 9009–9016
91. Zhou, X.; Sun, H.; Chen, H.; Zavadil, J.; Kluz, T.; Arita, A.; Costa, M. Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase. Cancer Res. 2010, 70, 4214–4221
92. Tausendschon, M.; Dehne, N.; Brune, B. Hypoxia causes epigenetic gene regulation in macrophages by attenuating Jumonji histone demethylase activity. Cytokine 2011, 53, 256–262
93. Black, J.C.; van Rechem, C.; Whetstine, J.R. Histone lysine methylation dynamics: Establishment, regulation, and biological impact. Mol. Cell 2012, 48, 491–507
94. Benlhabib, H.; Mendelson, C.R. Epigenetic regulation of surfactant protein a gene (sp-a) expression in fetal lung reveals a critical role for SUV39H methyltransferases during development and hypoxia. Mol. Cell. Biol. 2011, 31, 1949–1958
95. Hoffmann, I.; Roatsch, M.; Schmitt, M.L.; Carlino, L.; Pippel, M.; Sippl, W.; Jung, M. The role of histone demethylases in cancer therapy. Mol. Oncol. 2012, 6, 683–703
96. Yang, J.; Ledaki, I.; Turley, H.; Gatter, K.C.; Montero, J.C.; Li, J.L.; Harris, A.L. Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases. Ann. N. Y. Acad. Sci. 2009, 1177, 185–197
97. Sanchez-Fernandez, E.M.; Tarhonskaya, H.; Al-Qahtani, K.; Hopkinson, R.J.; McCullagh, J.S.; Schofield, C.J.; Flashman, E. Investigations on the oxygen dependence of a 2-oxoglutarate histone demethylase. Biochem. J. 2013, 449, 491–496
98. Cascella, B.; Mirica, L.M. Kinetic analysis of iron-dependent histone demethylases: α-ketoglutarate substrate inhibition and potential relevance to the regulation of histone demethylation in cancer cells. Biochemistry 2012, 51, 8699–8701
99. Beyer, S.; Kristensen, M.M.; Jensen, K.S.; Johansen, J.V.; Staller, P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J. Biol. Chem. 2008, 283, 36542–36552
100. Pollard, P.J.; Loenarz, C.; Mole, D.R.; McDonough, M.A.; Gleadle, J.M.; Schofield, C.J.; Ratcliffe, P.J. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1[1]. Biochem. J. 2008, 416, 387–394
101. Luo, W.; Chang, R.; Zhong, J.; Pandey, A.; Semenza, G.L. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc. Natl. Acad. Sci. USA 2012, 109, E3367–E3376
102. Krieg, A.J.; Rankin, E.B.; Chan, D.; Razorenova, O.; Fernandez, S.; Giaccia, A.J. Regulation of the histone demethylase jmjd1a by hypoxia-inducible factor 1 [1] enhances hypoxic gene expression and tumor growth. Mol. Cell. Biol. 2010, 30, 344–353
103. Fu, L.; Chen, L.; Yang, J.; Ye, T.; Chen, Y.; Fang, J. HIF-1[1]-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism. Carcinogenesis 2012, 33, 1664–1673
104. Hancock, R.L.; Dunne, K.; Walport, L.J.; Flashman, E.; Kawamura, A. Epigenetic regulation by histone demethylases in hypoxia. Epigenomics 2015, 2, 1–21
105. Graeber, T.G.; Osmanian, C.; Jacks, T.; Housman, D.E.; Koch, C.J.; Lowe, S.W.; Giaccia, A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379, 88–91
106. Leszczynska, K.B.; Foskolou, I.P.; Abraham, A.G.; Anbalagan, S.; Tellier, C.; Haider, S.; Span, P.N.; O’Neill, E.E.; Buffa, F.M.; Hammond, E.M. Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. J. Clin. Invest. 2015, 125, 2385–2398
107. Lachance, G.; Uniacke, J.; Audas, T.E.; Holterman, C.E.; Franovic, A.; Payette, J.; Lee, S. DNMT3A epigenetic program regulates the HIF-2[1] oxygen-sensing pathway and the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA 2014, 111, 7783–7788
108. Koh, M.Y.; Lemos, R., Jr.; Liu, X.; Powis, G. The hypoxia-associated factor switches cells from HIF-1[1]- to HIF-2[1]-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res. 2011, 71, 4015–4027
109. Geng, H.; Harvey, C.T.; Pittsenbarger, J.; Liu, Q.; Beer, T.M.; Xue, C.; Qian, D.Z. HDAC4 protein regulates HIF1[1] protein lysine acetylation and cancer cell response to hypoxia. J. Biol. Chem. 2011, 286, 38095–38102
110. Mie Lee, Y.; Kim, S.H.; Kim, H.S.; Jin Son, M.; Nakajima, H.; Jeong Kwon, H.; Kim, K.W. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1[1] activity. Biochem. Biophys. Res. Commun. 2003, 300, 241–246
111. Fischer, C.; Leithner, K.; Wohlkoenig, C.; Quehenberger, F.; Bertsch, A.; Olschewski, A.; Olschewski, H.; Hrzenjak, A. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1[1] destabilization. Mol. Cancer 2015, doi:10.1186/1476-4598-14-4
112. Gryder, B.E.; Sodji, Q.H.; Oyelere, A.K. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. Future Med. Chem. 2012, 4, 505–524
113. Wagner, T.; Jung, M. New lysine methyltransferase drug targets in cancer. Nat. Biotechnol. 2012, 30, 622–623
114. Lakshmikuttyamma, A.; Scott, S.A.; de Coteau, J.F.; Geyer, C.R. Reexpression of epigenetically silenced aml tumor suppressor genes by SUV39H1 inhibition. Oncogene 2010, 29, 576–588
115. Tran, H.T.; Kim, H.N.; Lee, I.K.; Nguyen-Pham, T.N.; Ahn, J.S.; Kim, Y.K.; Lee, J.J.; Park, K.S.; Kook, H.; Kim, H.J. Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A. J. Korean Med. Sci. 2013, 28, 237–246
116. Huang, Y.; Greene, E.; Murray Stewart, T.; Goodwin, A.C.; Baylin, S.B.; Woster, P.M.; Casero, R.A., Jr. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc. Natl. Acad. Sci. USA 2007, 104, 8023–8028
117. Huang, Y.; Stewart, T.M.; Wu, Y.; Baylin, S.B.; Marton, L.J.; Perkins, B.; Jones, R.J.; Woster, P.M.; Casero, R.A.,. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin. Cancer Res. 2009, 15, 7217–7228
118. Lohse, B.; Kristensen, J.L.; Kristensen, L.H.; Agger, K.; Helin, K.; Gajhede, M.; Clausen, R.P. Inhibitors of histone demethylases. Bioorg. Med. Chem. 2011, 19, 3625–3636.